Huberman Joins Hims Board in Multimillion-Dollar Deal

Andrew Huberman, the Stanford neuroscientist whose Huberman Lab podcast has become a dominant force in health and wellness media, is taking a formal role at telehealth company Hims & Hers. Huberman joins Hims board as a director and will also advise the company on science and brand marketing, while his media company will provide podcast advertising services. The arrangement, disclosed in an SEC filing, includes a compensation package worth roughly $5.9 million annually before any short-form advertising work.

A lucrative and multi-layered partnership

Neurobiology Professor and host of the Huberman Lab podcast Andrew Huberman

The financial terms are extensive. Huberman will receive a $3.5 million annual cash fee for two years to advise Hims on science and brand marketing. Scicomm Media, which Huberman co-owns, will get $5 million per year for up to three years for podcast advertising, with Hims estimating Huberman’s personal interest in that deal at about $2.1 million annually. He can also earn up to $1 million more per year by producing short-form videos for Hims’ paid advertising channels. His board package is valued at $300,000 annualized, including a cash retainer and equity award, prorated for his initial term—placing him near the top of Hims’ director pay scale, alongside former FDA Deputy Commissioner Deb Autor.

Huberman’s board seat carries fiduciary duties, distinguishing this from prior advisory roles he has held with fitness and sleep brands. He will join a board that includes former Netflix CFO David Wells and former DoorDash CMO Kofi Amoo-Gottfried.

Shared vision for accessible care

Hims & Hers CEO Andrew Dudum

Huberman told Business Insider that he first contacted Hims CEO Andrew Dudum through a mutual friend, and the two spent six to eight months discussing the future of consumer healthcare. Both described a shared ambition to make personalized healthcare more accessible. Huberman said he sees Hims as filling a gap between a traditional system where patients struggle for time and attention and high-end concierge care, arguing that “the middle 95%” should have access to personalized care.

Dudum, speaking on a joint call, framed the goal as empowering people globally to feel better and take more agency in their lives. Hims has nearly 3 million customers and operates its own pharmacy and manufacturing infrastructure, giving it a sizable platform for expanding into new areas.

Betting on optimization and peptides

Huberman’s appointment comes as Hims pushes into optimization-focused services such as testosterone and peptides. Huberman has been a prominent mainstream voice on injectable peptides, while Dudum has been building Hims to sell them. The company signed a deal for a California peptide facility at the end of 2024 and announced the acquisition in February 2025. By May, Dudum told investors he was following peptide innovation closely, citing potential uses in pain management, recovery, and longevity. Hims has previewed a forthcoming Peptides+ section where consumers could access peptides like BPC-157, along with wellness therapies such as NAD+ and vitamin B12, once regulatory approval permits.

Huberman said he does not want to encourage broad peptide use among people who don’t need them, noting uncertainty about whether someone without an injury needs BPC and TB-500. Still, he cited Hims’ plans to control peptide manufacturing from start to finish as a major selling point for joining the board, along with the company’s commitment to leading the conversation about what peptides can and cannot do. “You have to be a channel, not a dam to this kind of information,” he said. Dudum similarly said the emerging world of personalized health and longevity needs to be navigated carefully and cautiously.

Editorial independence questions

The Huberman Lab YouTube channel has more than 8 million subscribers, and the podcast is regularly among the most popular in its category. Huberman said his content will continue to cover benefits, risks, and uncertainty across health topics. “We will never filter information differently because of a brand relationship,” he told Business Insider. He added that Hims has encouraged him to continue providing education independent of any product or platform.

He did not specify how each podcast episode, social post, or short clip will disclose his board seat and separate marketing relationship with Hims. The arrangement places Huberman in the unusual position of advising audiences on how to navigate the wellness economy while helping market one of its biggest players.

Leave a comment

Your email address will not be published. Required fields are marked *